Simufilam in Alzheimer's Disease: Assessment of Efficacy of a Controversial Drug in Human Neuronal Cell Culture.
Confidence:
0.13
· 7 полей извлечено
Идентификация (6 полей)
Target
BACE1
0.90
Alt. target
—
0.00
Protein family
—
0.00
Functional class
—
0.00
Subcellular loc.
—
0.00
Isoforms (metab/obesity)
—
0.00
Механизм действия (21 полей)
Mechanism
—
0.00
Mutations (obesity/lean)
—
0.00
Activity (obesity)
—
0.00
Activity temporal
—
0.00
Energy balance
—
0.00
Appetite
—
0.00
Fat metabolism
—
0.00
Lipolysis
—
0.00
Thermogenesis
—
0.00
Muscle metabolism
—
0.00
Inflammation
—
0.00
Glucose metabolism
—
0.00
AA metabolism
—
0.00
Hormonal pathways
—
0.00
Cell death
—
0.00
Adipocyte fibrosis
—
0.00
Upstream (biochem)
—
0.00
Upstream (physiol)
—
0.00
Downstream (biochem)
—
0.00
Downstream (physiol)
—
0.00
PTMs
—
0.00
Экспрессия (8 полей)
Tissue expression
—
0.00
In vitro
Human neuronal cell culture; Mesenchymal stem cell-derived rapid drug screening system; Human microglia-like cellular model
0.90
In vivo
Preliminary in vivo insights mentioned in one study title
0.70
In silico
In silico candidate repurposed drugs; In silico profiling of hydrazide-hydrazone indole congeners
0.90
Genetic association
Assessment of neurodegenerative disease gene variants in human microglia-like cellular model
0.80
Ex vivo
—
0.00
Animal model
—
0.00
Diet/model
—
0.00
Клиника (11 полей)
Drug
Simufilam
0.95
Indication
Alzheimer's Disease
0.95
Patient subgroups
—
0.00
Safety concerns
—
0.00
Off-target
—
0.00
Trial stage
—
0.00
Pharma competitors
—
0.00
AE severity
—
0.00
MOA weight loss
—
0.00
Endpoints
—
0.00
Approved
—
0.00